1. Introduction
===============

Tumors of the central nervous system (CNS) account for about 2% of all cancers, and its morbidity is about 4.2/10^5^ to 5.4/10^5^ people per year, worldwide \[[@b1-ijms-14-03314]\]. Although the incidence of CNS tumors is small, compared with other cancers, these are among the most serious human malignancies, since they affect coordination and the integration of all organic activities. Moreover, as each region of the brain has a vital function, total surgical removal of the organ or tumor, which is used with other cancers, cannot be applied to cure brain tumors \[[@b2-ijms-14-03314]\]. Gliomas are the most common tumors of the CNS. Despite the remarkable progress in the characterization of the molecular pathogenesis of gliomas, these tumors remain incurable and, in most cases, resistant to treatment due to their molecular heterogeneity.

Although many studies have been conducted on the etiology of glioma, it is still not completely understood. The only established environmental risk factors are ionizing radiation and ultraviolet rays, and the low exposure to these types of radiation, in daily life, may explain the low incidence rate of this cancer \[[@b3-ijms-14-03314],[@b4-ijms-14-03314]\]. Both types of radiation cause an accumulation of DNA damage, including oxidative DNA damage, single- and double-strand breaks in DNA chains, and DNA--DNA or DNA--protein cross-links. This DNA damage may lead to tumor development and various cellular dysfunctions \[[@b5-ijms-14-03314]\]. Several complex systems of DNA repair work against DNA damage and prevent mutagenesis, including base excision repair (BER), nucleotide excision repair (NER), double-strand break repair (SSBR), and homologous recombination repair (HRR). BER, NER, and HRR, constitute the main defenses against lesions generated by ionizing radiation, alkylating agents, and reactive oxygen species \[[@b6-ijms-14-03314]\]. The excision repair cross-complementing rodent repair deficiency complementation group 1 (ERCC1) gene is reported to be a crucial gene in the NER pathway, and ERCC1 polymorphisms can modify the function of NER and, thus, influence the risk of human cancers. X-ray repair cross-complementing groups 1 (XRCC1) polymorphisms facilitate the BER and SSBR processes \[[@b7-ijms-14-03314]--[@b9-ijms-14-03314]\]. X-ray repair cross-complementing groups 3 (XRCC3) participates in DNA double-strand break/recombination repair, and likely also participates in HRR \[[@b10-ijms-14-03314]\].

Several common and putatively functional single nucleotide polymorphisms (SNPs) of ERCC1, XRCC1, and XRCC3 have been identified, of which ERCC1 C118T and ERCC1 C8092A affect ERCC1 mRNA expression, whereas XRCC1 Arg194Trp and XRCC1 Arg399Gln, and XRCC3 Thr241Met are associated with suboptimal DNA repair capacity \[[@b9-ijms-14-03314],[@b11-ijms-14-03314]\], and with an altered risk of several types of cancer \[[@b12-ijms-14-03314]--[@b15-ijms-14-03314]\]. Possible associations of polymorphisms in ERCC1 and XRCC1 genes with glioma risk have been examined in European populations with conflicting results \[[@b16-ijms-14-03314]--[@b19-ijms-14-03314]\]. However, there have been few reports about the independent and combined roles of ERCC1, XRCC1, and XRCC3 polymorphisms in Chinese populations. Therefore, we conducted a large case-control study to investigate whether there is an association between glioma risk and polymorphisms in these three genes, in a Chinese population.

2. Results and Discussion
=========================

2.1. Results
------------

A total of 478 cases were asked to participate, of whom 443 were successfully interviewed, and provided 5 mL blood samples, for a participation rate of 92.7%. The mean ages of the cases, and controls, were 50.9 ± 9.6 years and 51.2 ± 9.1 years, respectively ([Table 1](#t1-ijms-14-03314){ref-type="table"}). There were no significant differences in the ages or sex distributions between the two groups (*p* \> 0.05). However, the glioma patients were more likely to have had a greater exposure history to occupational IR (4.6% *vs.* 1%, *p* \< 0.05) and a family history of cancer when compared to the controls (21.4 *vs.* 11.7, *p* \< 0.05). Of the cancer cases, 49.5% were astrocytoma.

The minor allele frequencies, among selected controls of ERCC1 C118T, ERCC1 C8092A, XRCC1 Arg194Trp, XRCC1 Arg399Gln and XRCC3 Thr241Met, were consistent with the Minor Allele Frequency (MAF) from the NCBI SNP database ([Table 2](#t2-ijms-14-03314){ref-type="table"}). ERCC1 C118T, ERCC1 C8092A, XRCC1 Arg194Trp, XRCC1 Arg399Gln, and XRCC3 Thr241Met, were in line with the Hardy-Weinberg equilibrium in controls (all *p* values \> 0.05).

The genotype distributions of ERCC1 C8092A and XRCC3 Thr241Met were significantly different between cases and controls ([Table 3](#t3-ijms-14-03314){ref-type="table"}). Associations between these SNPs, and the risk of glioma, were analyzed using conditional logistical regression analysis, with frequency matched by age and sex. For XRCC1 Arg194Trp, the variant genotype T/T was strongly significantly associated with a lower risk of glioma cancer, when compared with the wild-type C/C, with an adjusted OR (95% CI) of 2.45 (1.43--4.45). The XRCC1 194T allele was associated with elevated susceptibility to glioma (OR = 1.76, 95% CI = 1.21--2.06). Individuals carrying the XRCC1 399A allele had a higher risk of glioma (OR = 1.33, 95% CI = 1.02--1.64), as did those with the XRCC3 241T/T genotype (OR = 3.78, 95%CI = 1.86--9.06). The T allele of XRCC3 Thr241Met was significantly associated with a small increased risk of glioma (OR = 1.38, 95% CI = 1.04--1.65).

A further association analysis was conducted to identify the interactions of two susceptibility-associated SNPs, XRCC1 Arg194Trp, and XRCC3 Thr241Met, and their impact on glioma risk. The combination genotype of the XRCC1 194T allele and the XRCC3 241T allele was associated with higher glioma risk (OR = 2.75, 95% CI = 1.54--4.04) ([Table 4](#t4-ijms-14-03314){ref-type="table"}).

2.2. Discussion
---------------

In this case-control study in a Chinese population, we identified the separate and combined effects on the risk of glioma of polymorphisms in ERCC1 C118T, ERCC1 C8092A, XRCC1 Arg194Trp, XRCC1 Arg399Gln, and XRCC3 Thr241Me. We found that XRCC1 194T/T and XRCC3 241T/T were strongly associated with glioma cancer risk, both individually and in combination.

To the best of our knowledge, our study is the first to describe the associations of these DNA repair gene polymorphisms with glioma risk in a Chinese population. Previous studies have focused on only one or two variants in the ERCC1 and XRCC1 genes, which might not sufficiently capture the effect of susceptibility loci in Chinese glioma patients. A recent Brazilian study, with 80 glioma cases and 100 controls, found that XRCC1 194T/T is associated with a strong increased risk of glioma \[[@b19-ijms-14-03314]\]. Another study conducted in southern China, with 127 glioma cases, showed that the homozygous T/T and heterozygotes C/T variants of XRCC1 codon 194, brought a 2.12-fold and 1.46-fold increased risk of glioma when compared to the homozygous wild-type genotype \[[@b20-ijms-14-03314]\]. Our findings strongly indicate that polymorphisms in XRCC1 Arg194Trp and XRCC3 Thr241Met contribute to glioma susceptibility, and are in line with those of previous studies showing that the XRCC1 194T allele is associated with increased glioma risk \[[@b19-ijms-14-03314],[@b20-ijms-14-03314]\]. However, other studies have obtained conflicting results. One hospital-based study, with 271 cases, reported a non-significant association between the XRCC1 194T allele and glioma risk \[[@b21-ijms-14-03314]\], and another large sample study with 701 cases also reported a non-significant increased risk of glioma \[[@b18-ijms-14-03314]\]. The inconsistency of these studies may be explained by differences in genetic origin, population background, source of controls, and sample size, or by chance. Alternatively, gene-environment interactions may operate in the pathogenesis of glioma, and thus differences in environmental risk factors may affect glioma risk.

Our study found a slight increased risk of glioma for patients with XRCC1 399Gln/Gln. Several previous studies have also shown that this allele is a risk factor for glioma \[[@b20-ijms-14-03314]--[@b23-ijms-14-03314]\]. In a recent study in a Caucasian population, with 373 glioma patients and 365 controls, there was an increased risk of glioma among patients with the XRCC1 399 A/A genotype \[[@b23-ijms-14-03314]\]. Another study reported that this genotype carried a 3.5-fold risk of glioma in a Turkish population \[[@b22-ijms-14-03314]\]. This solidly positive association from above studies seems to be in line with the well-documented functional relevance of this genotype. As far as we know, the XRCC1 Arg399Gln SNP has been a particular research focus, mainly due to its location within the BRCT1 binding domain \[[@b24-ijms-14-03314],[@b25-ijms-14-03314]\], which interacts with Poly(ADP-ribose)polymerase-1(PARP-1), and thus may result in deficient DNA repair. More recently, Taylor *et al.* showed that the BRCT domain is critical for efficient single-strand break repair and cell survival \[[@b11-ijms-14-03314]\], and that mutations of the BRCT1 domain of BRCA1 may alter the function of the tumor suppressor gene, and thus increase susceptibility to glioma \[[@b26-ijms-14-03314]\]. XRCC1 Arg399Gln expression is reportedly associated with increased gene expression, as measured by mRNA levels in breast cancer patients \[[@b12-ijms-14-03314]\]. Actually, there was no elevated DNA repair activity in the variant cells. The elevated gene expression might be induced by the variant in a structural region of the gene that theoretically influence the enzyme function but not gene expression

We found that patients with homozygous wild-type genotype XRCC3 had a higher risk of glioma than did those with other genotypes. Similar associations have been identified for other types of cancer, including breast cancer, lung cancer, colorectal cancer, skin melanoma, and gastric cancer \[[@b14-ijms-14-03314],[@b15-ijms-14-03314],[@b27-ijms-14-03314]--[@b30-ijms-14-03314]\]. One meta-analysis reported that the XRCC3 241T allele is associated with increased risk for breast cancer in Asian and Caucasian populations \[[@b30-ijms-14-03314]\]. Polymorphisms in DNA repair genes may be associated with differences in repair of DNA damage, and thus influence the risk for developing tumors \[[@b31-ijms-14-03314]\]. An association between cancer risk and XRCC3 Thr241Met was also found in glioma patients in previous studies. A study conducted in a Chinese population, with a large sample size, showed that the XRCC3 241T/T genotype may contribute to the development of glioma \[[@b23-ijms-14-03314]\], and a Brazilian study reported a strongly increased risk of glioma among patients with the 241T allele \[[@b13-ijms-14-03314]\]. Our data showed that the XRCC3 241T allele had the similar role in previous studies for glioma risk, suggesting that XRCC3 Thr241Met is involved in susceptibility for developing glioma.

The combination of the XRCC1 194T and XRCC3 241T alleles was also strongly associated with glioma in our study. This combination effect could be explained by the additive effect of the two genotypes. This additive effect of XRCC1 and XRCC3 has also been reported in a western population \[[@b18-ijms-14-03314]\].

3. Experimental Section
=======================

3.1. Study Subjects
-------------------

This case-control study was conducted at the Shengjing Affiliated Hospital of China Medical University. Between October 2007 and January 2012, all hospital patients with newly diagnosed, histologically confirmed primary gliomas, whose first visit fell within two months of initial diagnosis, were asked to participate in the study. Those who consented were interviewed and provided 5 mL blood samples. Controls were selected from among inpatients from the orthopedics, dermatology, and digestive departments; controls had to lack a prior history of cancer, and were frequency matched to cases by age (within 5 years), and sex.

A self-designed questionnaire was used to collect data on demographics and potential risk factors, including smoking, alcohol consumption, and family history of cancer, as well as occupational infrared ray (IR) exposure history.

The research protocol was approved by the ethics committees of the Shengjing Affiliated Hospital of China Medical University, and informed consent was obtained from all recruited subjects.

3.2. Genotyping
---------------

DNA was extracted from the buffy-coat fractions with the TIANamp blood DNA kit (Tiangen Biotech, Beijing, China). SNP genotyping was performed in a 384-well plate format on the Sequenom MassARRAY platform (Sequenom, San Diego, CA, USA). Primers for polymerase chain reaction (PCR) amplification and single base extension (SBE) assays were designed by Sequenom Assay Design 3.1 software (Sequenom, San Diego, CA, USA) according to the manufacturer's instructions ([Table 5](#t5-ijms-14-03314){ref-type="table"}). The PCR was performed with 5 ng of genomic DNA, in a reaction volume of 5 μL, using GeneAmp^®^ PCR System 9700 with Dual 384-Well Sample Block Module (Applied Biosystems, Carlsbad, CA, USA). The excess dNTPs was removed by shrimp alkaline phosphatase enzyme solution (Sequenom), and iPLEX^®^ Gold SBE chemistry (Sequenom) was used to perform base extension reaction. The final base extension products were treated with CLEAN resin (Sequenom) to remove salts. A total of 10 nL of reaction solution was dispensed onto a 384 format SpectroCHIP microarray (Sequenom). The MassARRAY Analyzer Compact with ACQUAIRE Module (Sequenom) acquired spectra from the SpectroCHIP, and spectral data were automatically processed and saved to the MassARRAY database. For quality control, genotyping was performed without knowledge of the case/control status of the subjects, and a random sample of 5% of cases and controls was genotyped again by different researchers. The reproducibility was 100%. DNA extraction and SNP genotyping were conducted in the Shengjing Affiliated Hospital of China Medical University.

3.3. Statistical Analysis
-------------------------

All statistical analyses were performed by Stata 8.0 (StataCorp, College Station, USA) and conducted by Dr. W.R. Pan WR. Continuous variables were expressed as mean ± standard deviation (SD), while categorical variables were shown as frequencies and percentages. Demographic characteristics were compared between cases and controls by means of a chi-square test and Student's t test. The Hardy-Weinberg equilibrium (HWE) was checked for controls with the chi-square test. Conditional logistic regression was used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). Because of the low allele frequencies, and relative rarity of the homozygous variant genotypes, we combined the homozygous variant and heterozygous groups for analysis. All comparisons were two-sided, and *p* \< 0.05 was regarded as statistically significant.

4. Conclusions
==============

In conclusion, we found that the polymorphisms XRCC1 Arg194Trp, XRCC1 Arg399Gln, and XRCC3 Thr241Met, were significantly associated with glioma cancer susceptibility among Chinese women, and that the combination of XRCC1 194T allele and XRCC3 241T allele was even more strongly associated with elevated glioma risk. Our results support the hypothesis that naturally occurring genetic variation in the X-ray repair cross-complementing group of genes increases susceptibility to glioma.
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###### 

Characteristics of glioma cases and controls.

  --------------------------------------------------------------------------------------------------
  Characteristics                        Cases\       \%     Controls\    \%     χ^2^    *p* value
                                         *N* = 443           *N* = 443                   
  -------------------------------------- ------------ ------ ------------ ------ ------- -----------
  Age (mean ± SD), years                 50.9 ± 9.6          51.2 ± 9.1                  

  **Age (years)**                                                                        

  \<30                                   73           16.4   70           15.7   115.2   0.95

  30--50                                 152          34.2   155          35.1           

  \>50                                   219          49.4   218          49.2           

  **Gender**                                                                             

  Male                                   257          58.0   257          58.0   0       1.0

  Female                                 186          42.0   186          42.0           

  **Smoking status**                                                                     

  Smokers                                152          34.2   121          27.4   5.09    \<0.05

  Non-smokers                            291          65.8   322          72.6           

  **Drinking status**                                                                    

  Drinkers                               212          47.8   197          44.5   1.02    0.31

  Non-drinkers                           231          52.2   246          55.5           

  **Occupational IR exposure history**                                                   

  Yes                                    20           4.6    4            1      3.82    \<0.05

  No                                     423          95.4   439          99             

  **Family history of cancer**                                                           

  Yes                                    95           21.4   52           11.7   15.08   \<0.05

  No                                     348          78.6   391          88.3           

  **Histological type**                                                                  

  Astrocytoma                            250          56.5                               

  Ependymoma                             27           6.2                                

  Glioblastoma                           59           13.3                               

  Oligodendroglioma                      11           2.5                                

  Other                                  95           21.5                               
  --------------------------------------------------------------------------------------------------

###### 

Genotype characteristics of the five single nucleotide polymorphisms (SNPs).

  Gene name         Single nucleotide polymorphism   Alleles   MAF [a](#tfn1-ijms-14-03314){ref-type="table-fn"}   HWE (*p* value) [b](#tfn2-ijms-14-03314){ref-type="table-fn"} Control          
  ----------------- -------------------------------- --------- --------------------------------------------------- ----------------------------------------------------------------------- ------ -------
  ERCC1 C118T       rs11615                          T/C       0.372                                               0.341                                                                   0.36   0.306
  ERCC1 C8092A      rs3212986                        G/T       0.292                                               0.275                                                                   0.25   0.133
  XRCC1 Arg194Trp   rs1799782                        C/T       0.191                                               0.148                                                                   0.13   0.103
  XRCC1 Arg399Gln   rs25487                          G/A       0.275                                               0.249                                                                   0.26   0.419
  XRCC3 Thr241Met   rs861539                         T/C       0.287                                               0.246                                                                   0.25   0.092

Minor Allele Frequency;

Hardy-Weinberg equilibrium.

###### 

Genotype distributions and association with glioma cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Single nucleotide polymorphism    Cases *N* = 443   \%     Controls\   *%*    *p* value   OR [a](#tfn3-ijms-14-03314){ref-type="table-fn"} (95% CI)   OR [b](#tfn4-ijms-14-03314){ref-type="table-fn"} (95% CI)
                                                             *N* = 443                                                                                  
  --------------------------------- ----------------- ------ ----------- ------ ----------- ----------------------------------------------------------- -----------------------------------------------------------
  **ERCC1 C118T (rs11615)**                                                                                                                             

  T/T                               193               43.5   211         47.6   0.45        1.0 (Ref.)                                                  1.0 (Ref.)

  C/T                               171               38.6   162         36.6               1.15 (0.85--1.56)                                           1.32 (0.89--1.67)

  C/C                               79                17.9   70          15.8               1.23 (0.83--1.83)                                           1.38 (0.91--1.94)

  C allele                          250               56.5   232         52.4               1.18 (0.89--1.55)                                           1.27 (0.96--1.67)

  **ERCC1 C8092A (rs3212986)**                                                                                                                          

  G/G                               229               51.8   241         54.3   \<0.05      1.0 (Ref.)                                                  1.0 (Ref.)

  G/T                               169               38.1   162         36.5               1.10 (0.82--1.47)                                           1.24 (0.93--1.61)

  T/T                               45                10.1   41          9.2                1.15 (0.71--1.88)                                           1.30 (0.88--1.93)

  T allele                          214               48.2   202         45.7               1.16 (0.87--1.54)                                           1.33 (0.98--1.66)

  **XRCC1 Arg194Trp (rs1799782)**                                                                                                                       

  C/C                               301               67.9   327         73.8   0.06        1.0 (Ref.)                                                  1.0 (Ref.)

  C/T                               116               26.1   101         22.9               1.24 (0.91--1.72)                                           1.36 (0.97--1.83)

  T/T                               27                6      15          3.3                1.98 (1.01--4.03)                                           2.45 (1.43--4.45)

  T allele                          142               42.6   116         34.8               1.33 (0.98--1.80)                                           1.76 (1.21--2.06)

  **XRCC1 Arg399Gln (rs25487)**                                                                                                                         

  G/G                               226               51.1   244         55.1   0.4         1.0 (Ref.)                                                  1.0 (Ref.)

  G/A                               190               42.8   178         40.1               1.15 (0.87--1.53)                                           1.28 (0.97--1.66)

  A/A                               27                6.1    21          4.8                1.39 (0.73--2.66)                                           1.54 (0.88--2.87)

  A allele                          217               64.9   199         59.6               1.19 (0.90--1.55)                                           1.33 (1.02--1.64)

  **XRCC3 Thr241Met (rs861539)**                                                                                                                        

  C/C                               217               48.9   234         52.8   \<0.05      1.0 (Ref.)                                                  1.0 (Ref.)

  C/T                               198               44.8   200         45.2               1.07 (0.81--1.41)                                           1.22 (0.96--1.54)

  T/T                               28                6.3    9           2                  3.35 (1.49--8.25)                                           3.78 (1.86--9.06)

  T allele                          226               67.8   209         62.6               1.17 (0.89--1.53)                                           (1.04--1.65)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Not adjusted;

Adjusted for smoking, alcohol drinking, and family history of cancer, as well as occupational infrared ray (IR) exposure history; Ref.: reference.

###### 

Interactions of XRCC1 A194T and XRCC3 C241T in cases and controls on glioma risk.

  -------------------------------------------------------------------------------------------------------------------
  Single nucleotide polymorphism        Cases\      \%     Controls\   *%*    OR (95% CI)         OR (95% CI)
                                        *N* = 443          *N* = 443                              
  ------------------------------------- ----------- ------ ----------- ------ ------------------- -------------------
  **XRCC1 Arg194Trp/XRCC3 Thr241Met**                                                             

  CC/CC                                 140         31.6   149         33.6   1.0 (Ref.)          1.0 (Ref.)

  T allele/CC                           77          17.4   85          19.2   1.02 (0.64--1.44)   1.12 (0.78--1.61)

  CC/T allele                           161         36.3   178         40.2   0.98 (0.71--1.37)   1.03 (0.83--1.52)

  T allele/T allele                     65          14.7   31          7.0    2.24 (1.35--3.76)   2.75 (1.54--4.04)
  -------------------------------------------------------------------------------------------------------------------

Ref.: reference.

###### 

PCR primers of selected SNPs.

  Single nucleotide polymorphism   Primer                           Sequence                         Extension primer
  -------------------------------- -------------------------------- -------------------------------- ------------------------
  ERCC1 C118T (rs11615)            1^st^-primer                     ACGTTGGATGCTAGACCCTAGCAACTCCAG   AGCAACTCCAGGCTAGAGGGCA
  2^nd^-primer                     ACGTTGGATGAATCAGCAGCGCGGACCCCT                                    
                                                                                                     
  ERCC1 C8092A (rs3212986)         1^st^-primer                     ACGTTGGATGGCTCACCTGGTGATGTCTT    CTGGTGATGTCTTGTTGATCC
  2^nd^-primer                     ACGTTGGATGTGAAGGAGGAGGATGAGAGC                                    
                                                                                                     
  XRCC1 Arg194Trp (rs1799782)      1^st^-primer                     ACGTTGGATGCCTAGCAACTCCAGGCTAGA   CTGGTGATGTCTTGTTGATCC
  2^nd^-primer                     ACGTTGGATGAGCCAATCAGCAGCGCGGAC                                    
                                                                                                     
  XRCC1 Arg399Gln (rs25487)        1^st^-primer                     ACGTTGGATGAGATGCTGGGTGATTGTTGG   GAGTGTGTGGGAGGGGAG
  2^nd^-primer                     ACGTTGGATGATCTTTCTGGCCATCTGTCC                                    
                                                                                                     
  XRCC3 Thr241Met (rs861539)       1^st^-primer                     ACGTTGGATGCAACCCTCTGTGAGTGTGTG   GAGTGTGTGGGAGGGGAG
  2^nd^-primer                     ACGTTGGATGAGCACCTCAGAGAGTACAAG                                    
